

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 July 2023 (27.07.2023)



(10) International Publication Number
WO 2023/141247 A3

(51) International Patent Classification:

A61K 31/713 (2006.01) A61K 31/712 (2006.01)
C12N 15/113 (2010.01) A61K 31/7125 (2006.01)
C12N 15/11 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/US2023/011200

(22) International Filing Date:

20 January 2023 (20.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/301,454 20 January 2022 (20.01.2022) US
63/328,629 07 April 2022 (07.04.2022) US

(71) Applicant: ALEXION PHARMACEUTICALS, INC.

[US/US]; 121 Seaport Boulevard, Boston, Massachusetts
02210 (US).

(72) Inventors; and

(71) Applicants: **DUDEK, Henryk T.** [US/US]; 75 Hayden
Avenue, Lexington, Massachusetts 02421 (US). **PARK,
Jihye** [KR/US]; 75 Hayden Ave., Lexington, Massachu-
setts 02421 (US). **BROWN, Bob Dale** [US/US]; 75 Hay-
den Ave., Lexington, Massachusetts 02421 (US). **LAI,
Chengjung** [US/US]; 75 Hayden Ave., Lexington, Massa-
chusetts 02421 (US). **KIM, SungKwon** [KR/US]; c/o Alex-
ion Pharmaceuticals, Inc., 121 Seaport Boulevard, Boston,
Massachusetts 02210 (US). **BEASLEY, Kathleen Nicole**
[US/US]; c/o Alexion Pharmaceuticals, Inc., Boston, Mass-
achusetts 02210 (US).

(72) Inventors: **LASARO, Melissa**; c/o Alexion Pharmaceuti-

cals, Inc., 121 Seaport Boulevard, Boston, Massachusetts
02210 (US). **MCKNIGHT, Susan Faas**; 14 Stonewood
Drive, Old Lyme, Connecticut 06371 (US).

(74) Agent: **HLAVKA, Christine M.**; Alexion Pharmaceuti-

cals, Inc., Attn.: Legal - Intellectual Property Dept., 100
College Street, New Haven, Connecticut 06510 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:

31 August 2023 (31.08.2023)

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING COMPLEMENT FACTOR B

(57) Abstract: Described herein are oligonucleotides (e.g., RNAi oligonucleotides) containing sense and antisense strands for targeting complement factor B (CFB) mRNA. The RNAi oligonucleotide may be used to inhibit CFB expression, levels, and/or activity in a cell. Also, described herein are methods for using an oligonucleotide (e.g., an RNAi oligonucleotide) for the prophylaxis or treatment of a disease, disorder, or condition mediated by complement pathway activation or dysregulation.

WO 2023/141247 A3